Skylands Capital LLC Acquires 29,350 Shares of Haemonetics Corporation $HAE

Skylands Capital LLC boosted its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 80.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,825 shares of the medical instruments supplier’s stock after purchasing an additional 29,350 shares during the period. Skylands Capital LLC owned about 0.14% of Haemonetics worth $3,710,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. AQR Capital Management LLC grew its position in shares of Haemonetics by 48.6% in the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after buying an additional 1,034,226 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after acquiring an additional 1,254,035 shares during the period. North Peak Capital Management LLC lifted its stake in Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after acquiring an additional 740,626 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Haemonetics by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after acquiring an additional 26,763 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH increased its position in Haemonetics by 17.3% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock valued at $47,400,000 after purchasing an additional 124,020 shares during the period. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HAE has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. Citigroup upped their price target on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a research note on Thursday, May 28th. Finally, Mizuho upped their price objective on shares of Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $78.33.

Haemonetics Stock Performance

Shares of HAE opened at $77.34 on Friday. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The business’s fifty day simple moving average is $65.41 and its two-hundred day simple moving average is $66.87. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The company has a market cap of $3.51 billion, a price-to-earnings ratio of 38.29, a P/E/G ratio of 1.56 and a beta of 0.56.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same period in the prior year, the company posted $1.24 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Research analysts anticipate that Haemonetics Corporation will post 5.22 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.